Healthcare company Perrigo Company plc (NYSE:PRGO) said on Monday that it is the first company to receive approval from the US Food and Drug Administration for its abbreviated new drug application (ANDA) for over-the-counter (OTC) diclofenac sodium topical gel 1% for the treatment of arthritis pain, with a launch later this year.
Through its prescription (Rx)-to-OTC switch process, the US FDA approved the company's Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for nonprescription or OTC use .
The company added the product will be marketed under retailer's store brand labels and will provide consumers with a high-quality, value alternative to GSK's Voltaren Arthritis Pain, which is indicated for the temporary relief of arthritis pain.
For the 12 months ending February 2020, the branded and generic prescription sales were USD250, according to IQVIA.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML